| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d9fa6c713683ad66db4819f31df3ac2b |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-737 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-737 |
| filingDate |
2012-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_959a4303d462017a5287cb290fcd8e7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3cc12f6d83dab14d56c2f3d73e568991
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3bad45d8e4906e586676cbf3082fe07d |
| publicationDate |
2013-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2779838-A1 |
| titleOfInvention |
Treatment of cytokine mediated conditions |
| abstract |
The present invention relates to the usefulness of a sulfated glycosaminoglycan (GAG) selected from the group consisting of heparan sulfate (HS), depolymerised heparan sulfate, dermatan sulfate (DS), depolymerised dermatan sulfate, low molecular weight heparin (LMWH), and depolymerised heparin having an anti-factor Xa activity of 200 IU/mg or less in treatment or prevention of at least one cytokine mediated condition of the endothelial or epithelial linings. |
| priorityDate |
2012-06-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |